Voiant
Voiant is recorded as a service provider in 35 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 35 trials · Latest update first
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Sponsor Aura Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
Sponsor Galderma S.A.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
Sponsor Ideaya Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Sponsor Alkeus Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease
Sponsor Tectonic Operating Company Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
Sponsor Aura Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Sponsor Tectonic Therapeutic Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-Blind, Controlled Study of XL092 in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor Exelixis Inc.
- Start (EU)
- Latest update
- Estimated end
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET (NETTER-2)
Sponsor Advanced Accelerator Applications
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis
Sponsor Zura Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)
Sponsor Endeavor Biomedicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- The study enrolled 124 participants at 122 sites across 18 countries; enrollment was highest in the United States (31), Brazil (19), and Italy (17).
- Recruitment started on 30 May 2022, and the global end-of-trial date was 14 January 2025.
- A protocol amendment changed planned enrollment from 90 to 80–100 participants.
- An amendment removed eGFR from the primary efficacy endpoint and moved primary and key secondary efficacy assessments from Week 52 to Week 26.
- An amendment increased the screening period from 8 to 10 weeks and total study participation duration to 70 weeks.
- Eligibility and dosing amendments increased the minimum body weight to 30 kg and added weight-based dosing regimens for adolescents.
- The minimum planned adolescent enrollment was increased from 8 to 10 participants.
- Follow-up for participants who did not continue pegcetacoplan was shortened from 24 to 8 weeks.
These findings describe the trial, not the service provider’s performance or responsibility.
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
Sponsor Neumora Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Voiant?
The 2026-10-09 snapshot links Voiant to 35 distinct CTIS trials. Recorded services include Imaging, Medical expertise, Central Imaging, Electronic data capture, among 27 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Voiant?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory, Immunology, Ophthalmology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Voiant conducted?
The linked trials record locations in 25 countries, including Spain, France, Germany, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Voiant delivered services.
What can this page tell me about Voiant's trial experience?
Browse 35 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Voiant. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Voiant
- Voiant LLC